M. Kulyk & Associates LLC Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

M. Kulyk & Associates LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,869 shares of the biopharmaceutical company's stock after selling 15,797 shares during the period. Gilead Sciences accounts for about 1.9% of M. Kulyk & Associates LLC's portfolio, making the stock its 17th biggest holding. M. Kulyk & Associates LLC's holdings in Gilead Sciences were worth $8,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $339,000. Quantbot Technologies LP bought a new position in shares of Gilead Sciences during the fourth quarter worth approximately $870,000. Sei Investments Co. raised its position in shares of Gilead Sciences by 18.1% in the fourth quarter. Sei Investments Co. now owns 760,358 shares of the biopharmaceutical company's stock valued at $70,235,000 after buying an additional 116,530 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $813,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 1.7%

Shares of GILD stock traded up $1.89 during trading hours on Tuesday, reaching $110.17. 4,487,230 shares of the company's stock were exchanged, compared to its average volume of 7,648,989. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock's fifty day moving average price is $108.81 and its two-hundred day moving average price is $105.35. The stock has a market cap of $137.04 billion, a PE ratio of 23.19, a PEG ratio of 0.70 and a beta of 0.29. Gilead Sciences, Inc. has a 1 year low of $70.78 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) earnings per share. The company's revenue was down .3% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $333,090.00. Following the transaction, the insider directly owned 117,168 shares in the company, valued at $13,009,163.04. The trade was a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the sale, the chief financial officer owned 162,610 shares of the company's stock, valued at $18,054,588.30. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,000 shares of company stock worth $7,844,775. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Oppenheimer cut their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Morgan Stanley lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Nine analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $111.38.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.